Nasdaq

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
PharmTech

FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025

George Tidmarsh and Vinay Prasad have taken leadership roles at CDER and CBER, respectively, impacting FDA's drug and ...
pharmaphorum

FDA’s emerging framework to reduce animal testing: Implications for drug development timelines, cost, and clinical strategy

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
Seeking Alpha

Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript

Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
PharmExec

Data Quality in Drug Development: The Missing Foundation to Realize AI’s Promise in Clinical Trials

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...
Detroit Free Press

NanoViricides Dual Track Clinical Strategy Explained by a Research Report – Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...